Sugi Predict

Sugi Predict / Compounds / SCHEMBL4148208

SCHEMBL4148208

SCHEMBL4148208

COC(=O)[C@@]1(C)CCC[C@@]2(C)[C@H]1CC(=O)[C@H]1[C@@H](C)/C(=C\C(=O)OCCN(C)C)CC[C@@H]12

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ATP1A1 P05023 3/20 0.73
▸ ATP1B1 P05026 3/20 0.73
▸ ATP1A3 P13637 3/20 0.73
▸ ATP1B2 P14415 3/20 0.73
▸ ATP1A2 P50993 3/20 0.73
▸ ATP1B3 P54709 3/20 0.73
▸ FXYD2 P54710 3/20 0.73
▸ ATP1A4 Q13733 3/20 0.73
▸ ATP12A P54707 3/20 0.73
▸ HSP90AA1 P07900 1/20 0.34
▸ MEN1 O00255 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30505265 1.00 ATP1A1 (0.73) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL6857608 1.00 ATP1A1 (0.73) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL6857605 1.00 ATP1A1 (0.73) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL5087938 0.87 ATP12A (0.81) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Cassaine SCHEMBL4167834 0.85 ATP12A (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Cassaine SCHEMBL4167835 0.85 ATP12A (1.00) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL30124557 0.83 ATP1A1 (0.51) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
Cassaine SCHEMBL7805406 0.82 ATP12A (0.93) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL5082160 0.79 ATP1A1 (0.71) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL11892867 0.77 ATP12A (0.84) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104150808-B For improving the method and additive of construction composition and substrate adherence 阿克佐诺贝尔化学国际公司 2017-11-17 — — CN disclosed
US-9353005-B2 Process for production of powder redispersible in water and use thereof AKZO NOBEL N.V. (NL) 2016-05-31 — — US disclosed
CN-102781869-B Method and additive for improving adhesion of building compositions to substrates AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2015-08-05 — — CN disclosed
CN-104150808-A Process and additive to improve adhesion of building compositions to substrates AKZO NOBEL CHEMICALS INT BV 2014-11-19 — — CN disclosed
US-20140316029-A1 PROCESS FOR PRODUCTION OF POWDER REDISPERSIBLE IN WATER AND USE THEREOF AKZO NOBEL N.V. (NL) 2014-10-23 — — US disclosed
CN-101272994-B Powder redispersible in water, process for production thereof and use thereof ELOTEX AG 2013-04-03 — — CN disclosed
CN-102781869-A Method and additive for improving adhesion of building compositions to substrates AKZO NOBEL CHEMICALS INT BV 2012-11-14 — — CN disclosed
US-20120264861-A1 POWDER REDISPERSIBLE IN WATER, PROCESS FOR PRODUCTION THEREOF AND USE THEREOF AKZO NOBEL N.V. (NL) 2012-10-18 — — US disclosed
US-20090223416-A1 POWDER REDISPERSIBLE IN WATER, PROCESS FOR PRODUCTION THEREOF AND USE THEREOF NATIONAL STARCH AND CHEMICAL INVESTMENT CORPORATION 2009-09-10 — — US disclosed
US-20080319375-A1 Materials, Methods, and Systems for Cavitation-mediated Ultrasonic Drug Delivery in vivo BIOVALUATION & ANALYSIS, INC. 2008-12-25 — — US disclosed
US-7056532-B1 Compositions for delivery of biological agents and methods for the preparation thereof Univ. Nebraska Bd. of Regents (US) 2006-06-06 — — US disclosed
EP-1005324-B1 COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF UNIV NEBRASKA (US) 2005-03-30 — — EP disclosed
US-6831101-B2 Compounds that bind to one or more RANTES receptors for treatment of chemokine mediated disease states CHEMOKINE THERAPEUTICS CORPORATION (CA) 2004-12-14 — — US disclosed
US-20030125380-A1 Tricyclic rantes receptor ligands CHEMOKINE THERAPEUTICS CORPORATION (CA) 2003-07-03 — — US disclosed
US-20030092674-A1 Tricyclic rantes receptor ligands CHEMOKINE THERAPEUTICS CORPORATION (CA) 2003-05-15 — — US disclosed
WO-2002102365-A1 TRICYCLIC TERPENES OF THE FAMILY OF ABIETIC ACID AS RANTES RECEPTOR LIGANDS CHEMOKINE THERAPEUTICS CORPORATION (CA) 2002-12-27 — — WO disclosed
EP-1005324-A4 COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF UNIV NEBRASKA (US) 2001-06-06 — — EP disclosed
EP-1005324-A1 COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) 2000-06-07 — — EP disclosed
WO-1998056334-A1 COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) 1998-12-17 — — WO disclosed
WO-1998056348-A1 COMPOSITIONS FOR DELIVERY OF BIOLOGICAL AGENTS AND METHODS FOR THE PREPARATION THEREOF UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) 1998-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125380-A1 Tricyclic rantes receptor ligands CCR5, CCR1, CCL11 ATP1A1 3992/4885ATP1B1 4547/4885ATP1A3 4718/4885
US-20030092674-A1 Tricyclic rantes receptor ligands CCR5, CCR1, CCL11 ATP1A1 3992/4885ATP1B1 4547/4885ATP1A3 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.